DE60012500D1 - Antikörper und antikörperfragmente mit spezifität für tgfbeta1 - Google Patents

Antikörper und antikörperfragmente mit spezifität für tgfbeta1

Info

Publication number
DE60012500D1
DE60012500D1 DE60012500T DE60012500T DE60012500D1 DE 60012500 D1 DE60012500 D1 DE 60012500D1 DE 60012500 T DE60012500 T DE 60012500T DE 60012500 T DE60012500 T DE 60012500T DE 60012500 D1 DE60012500 D1 DE 60012500D1
Authority
DE
Germany
Prior art keywords
sub
antibodies
tgfbeta1
specificity
antibody fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60012500T
Other languages
English (en)
Other versions
DE60012500T2 (de
Inventor
Elizabeth Thompson
Nicholas Lennard
Jane Wilton
Sally Braddock
Fou Leila Du
Gerald Mccafferty
Anne Conroy
Ronald Tempest
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
Cambridge Antibody Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Antibody Technology Ltd filed Critical Cambridge Antibody Technology Ltd
Application granted granted Critical
Publication of DE60012500D1 publication Critical patent/DE60012500D1/de
Publication of DE60012500T2 publication Critical patent/DE60012500T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
DE60012500T 1999-04-30 2000-05-02 Antikörper und antikörperfragmente mit spezifität für tgfbeta1 Expired - Lifetime DE60012500T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13198399P 1999-04-30 1999-04-30
US131983P 1999-04-30
PCT/GB2000/001679 WO2000066631A1 (en) 1999-04-30 2000-05-02 SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?

Publications (2)

Publication Number Publication Date
DE60012500D1 true DE60012500D1 (de) 2004-09-02
DE60012500T2 DE60012500T2 (de) 2005-08-11

Family

ID=22451886

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60012500T Expired - Lifetime DE60012500T2 (de) 1999-04-30 2000-05-02 Antikörper und antikörperfragmente mit spezifität für tgfbeta1

Country Status (15)

Country Link
US (3) US6492497B1 (de)
EP (1) EP1175445B1 (de)
JP (1) JP2003501348A (de)
AT (1) ATE272073T1 (de)
AU (1) AU768554B2 (de)
BR (1) BR0010162A (de)
CA (1) CA2370304A1 (de)
DE (1) DE60012500T2 (de)
ES (1) ES2225132T3 (de)
GB (1) GB2350612B (de)
IL (1) IL145813A0 (de)
MX (1) MXPA01010739A (de)
NO (1) NO20015261L (de)
NZ (1) NZ514759A (de)
WO (1) WO2000066631A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US6683156B1 (en) * 1996-08-27 2004-01-27 University Of South Florida Method for diagnosing selected adenocarcinomas
US7211644B1 (en) * 1996-08-27 2007-05-01 University Of South Florida Diagnostic markers of human female infertility
US8106001B2 (en) * 1996-08-27 2012-01-31 University Of South Florida Diagnostic markers of human female infertility
US6294662B1 (en) 1996-08-27 2001-09-25 University Of South Florida Nucleic acids encoding an endometrial bleeding associated factor (ebaf)
WO2001066754A1 (en) 2000-03-03 2001-09-13 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
EP1572937B1 (de) * 2002-04-09 2012-02-08 The Scripps Research Institute Hybrid-polypeptide mit eingefügten sequenzmotiven und ihre verwendungen
CA2494367A1 (en) * 2002-07-25 2004-02-05 Scios Inc. Methods for improvement of lung function using tgf-.beta. inhibitors
US20060286105A1 (en) * 2003-04-30 2006-12-21 Steven Ledbetter Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
AU2004259398A1 (en) 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
EP1646655A2 (de) * 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 liganden
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
EP1789074A4 (de) * 2004-08-09 2009-08-12 Alios Biopharma Inc Synthetische hyperglycosylierte, protease-resistente polypeptid-varianten, orale formulierungen und anwendungsverfahren dafür
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513542A (ja) * 2004-09-22 2008-05-01 ジェンザイム・コーポレイション 免疫抑制剤の腎毒性を制限するためのＴＧＦ−βアンタゴニストの使用
WO2006044433A2 (en) * 2004-10-13 2006-04-27 The Ohio State University Research Foundation Methods to treat or prevent viral-associated lymphoproliferative disorders
ES2711213T3 (es) * 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
EP1874818B1 (de) * 2005-04-22 2011-04-13 Eli Lilly And Company Tgf-beta-1-spezifische antikörper
EP2230252A1 (de) 2006-03-13 2010-09-22 The Johns Hopkins University Erhöhung der endothelialen Thromboresistenz
EP3254696A1 (de) 2006-10-03 2017-12-13 Genzyme Corporation Verwendung von tgf-beta-antagonisten zur behandlung von kleinkindern mit dem risiko des ausbruchs von bronchopulmonaler dysplasie
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
AU2009293658A1 (en) 2008-09-22 2010-03-25 James Cardia Reduced size self-delivering RNAi compounds
US20120071628A1 (en) * 2009-03-13 2012-03-22 Nihon University Topical therapeutic agent for ophthalmic diseases comprising compound capable of binding specifically to dna sequence
EP3560503B1 (de) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna-interferenz bei dermalen und fibrotischen erkrankungen
EP2550001B1 (de) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna-interferenz bei augenerkrankungen
KR102051014B1 (ko) 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
MX2014004994A (es) 2011-10-26 2014-08-27 Seattle Children S Res Inst Cisteamina en el tratamiento de enfermedad fibrotica.
EP2799537B1 (de) 2011-12-28 2021-09-22 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
US9518112B2 (en) 2012-03-08 2016-12-13 Ludwig Institute For Cancer Research Ltd TGF-β1 specific antibodies and methods and uses thereof
WO2013134665A1 (en) 2012-03-08 2013-09-12 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
TWI664979B (zh) 2013-03-11 2019-07-11 健臻公司 經生物工程之抗-ＴＧＦ-β抗體及抗原結合片段
NZ713219A (en) 2013-03-14 2017-04-28 Massachusetts Inst Technology Compositions and methods for epithelial stem cell expansion and culture
ES2700238T5 (es) * 2013-03-20 2022-05-20 Genzyme Corp Métodos para tratar la osteogénesis imperfecta
EP3816625A1 (de) 2013-05-06 2021-05-05 Scholar Rock, Inc. Zusammensetzungen und verfahren zur modulation von wachstumsfaktoren
EP3064222B1 (de) 2013-10-31 2020-10-21 Kyoto Prefectural Public University Corporation Therapeutikum enthaltend einen tgf-beta signalblocker für erkrankungen im zusammenhang mit endoplasmatischem retikulumszelltod im hornhautendothel
CN107073042A (zh) 2014-09-03 2017-08-18 布里格海姆妇女医院公司 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法
CA3008162A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
WO2016100233A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) * 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
CN108136001B (zh) 2015-04-03 2022-07-29 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
KR20180092947A (ko) * 2015-10-30 2018-08-20 더 리전츠 오브 더 유니버시티 오브 캘리포니아 형질 전환 성장 인자-베타-반응성 폴리펩티드 및 이의 사용 방법
EP3400286A1 (de) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Herstellung von differenzierten enteroendokrinen zellen und insulinproduzierenden zellen
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
CN109071646A (zh) 2016-03-11 2018-12-21 供石公司 TGFβ1-结合免疫球蛋白及其用途
WO2017201036A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
US11701384B2 (en) 2016-09-02 2023-07-18 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
KR20190104359A (ko) 2016-12-30 2019-09-09 프리퀀시 테라퓨틱스, 인크. 줄기/전구체 지지 세포의 자가 재생을 유도하기 위한 1h-피롤-2,5-다이온 화합물 및 이의 사용 방법
EP3551658A1 (de) 2017-01-06 2019-10-16 Scholar Rock, Inc. Isoformspezifische, kontextpermissive tgf-1-inhibitoren und verwendung davon
JP2020186172A (ja) * 2017-06-19 2020-11-19 株式会社ボナック 抗ＴＧＦ−β１抗体
JP2021502066A (ja) 2017-11-06 2021-01-28 ジェネンテック， インコーポレイテッド がんの診断及び療法
WO2019173692A2 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
JP2021518413A (ja) 2018-03-20 2021-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
EP3820896A1 (de) 2018-07-11 2021-05-19 Scholar Rock, Inc. Tgfbeta1-inhibitoren und verwendung davon
CA3105988A1 (en) 2018-07-11 2020-01-16 Abhishek Datta High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Ｊａｇ−１を上方制御することにより有毛細胞を生成するための組成物及び方法
EP3906233B1 (de) 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Kinaseinhibitorverbindungen und zusammensetzungen und verfahren zur verwendung
MA54845A (fr) 2019-01-30 2021-09-29 Scholar Rock Inc Inhibiteurs de ltbp propres à un complexe de tgf-béta et leurs utilisations
EP3947737A2 (de) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur vorhersage und vorbeugung von krebs bei patienten mit prämalignen läsionen
EP4007774A1 (de) 2019-08-01 2022-06-08 Vaccinex, Inc. Kombinierte hemmung von semaphorin-4d und tgfb und zusammensetzungen dafür
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Lab Inc Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3744595A1 (de) 1987-12-31 1989-07-13 Andreas Dr Plueckthun Verfahren zur gentechnischen herstellung von antikoerpern
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2057923A1 (en) 1989-05-16 1990-11-17 William D. Huse Co-expression of heteromeric receptors
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
WO1991004748A1 (en) 1989-09-29 1991-04-18 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
EP0564531B1 (de) 1990-12-03 1998-03-25 Genentech, Inc. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
EP0580737B1 (de) 1991-04-10 2004-06-16 The Scripps Research Institute Bibliotheken heterodimerer rezeptoren mittels phagemiden
JPH0768278B2 (ja) 1991-06-21 1995-07-26 メルシャン株式会社 トランスフォーミング成長因子β１に対するモノクローナル抗体
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
AU3609893A (en) 1992-01-29 1993-09-01 La Jolla Cancer Research Foundation Methods of controlling the proliferation of macrophages
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
MX9301135A (es) 1992-03-06 1993-09-01 Steven G Reed Metodo para tratar infecciones por patogeno de macrofago.
AU3943793A (en) 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
AU4111893A (en) 1992-04-23 1993-11-29 La Jolla Cancer Research Foundation Methods for treating vascular disorders by inhibiting the endothelin stimulatory activity of TGFbeta
WO1993023557A1 (en) * 1992-05-08 1993-11-25 Receptagen Corporation Anti-receptor agents to the vitamin b12/transcobalamin ii receptor
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
KR100310739B1 (ko) 1993-02-04 2002-05-30 알란 스코브 단백질재생을위한개선된방법
ATE315939T1 (de) 1993-11-19 2006-02-15 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
GB2288118A (en) 1994-03-29 1995-10-11 Univ Manchester Wound healing composition
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods

Also Published As

Publication number Publication date
NZ514759A (en) 2003-10-31
AU768554B2 (en) 2003-12-18
NO20015261L (no) 2001-12-21
NO20015261D0 (no) 2001-10-26
CA2370304A1 (en) 2000-11-09
DE60012500T2 (de) 2005-08-11
EP1175445A1 (de) 2002-01-30
ATE272073T1 (de) 2004-08-15
JP2003501348A (ja) 2003-01-14
ES2225132T3 (es) 2005-03-16
US6492497B1 (en) 2002-12-10
US7151169B2 (en) 2006-12-19
GB2350612A (en) 2000-12-06
IL145813A0 (en) 2002-07-25
GB2350612B (en) 2002-01-09
EP1175445B1 (de) 2004-07-28
GB0010568D0 (en) 2000-06-21
BR0010162A (pt) 2002-02-05
US20030091566A1 (en) 2003-05-15
AU4588600A (en) 2000-11-17
MXPA01010739A (es) 2003-08-20
WO2000066631A1 (en) 2000-11-09
US20030064069A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
ATE272073T1 (de) Antikörper und antikörperfragmente mit spezifität für tgfbeta1
WO2003060080A3 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
WO2002096948A3 (en) Engineered tetravalent antibodies and methods of use
MXPA02000119A (es) Elementos mezcladores estaticos apilados.
PT1157042E (pt) Produção de anticorpos tetravalentes
DK1438340T3 (da) Antistoffer mod KDR, deres fremstilling og anvendelser
BR0110927A (pt) Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
HK1048831A1 (en) Human ctla-4 antibodies and their uses
RS51829B (sr) Ljudska antitela specifična za interleukin 15 (il-15)
EP2305715A3 (de) Monoklonaler Antikörper gegen das Osteoprotegerin-bindenden Protein
HK1076128A1 (en) Humanized collagen antibodies and related methods
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
CA2068222A1 (en) Monoclonal antibodies
EP1486560A3 (de) Antikörper und Antikörperfragmente mit Spezifizität für TGF beta 1
WO2002026929A3 (en) Kini-3 motor protein and methods for its use
WO2002012541A3 (en) Novel motor proteins and methods for their use
WO2001096593A3 (en) Novel motor proteins and methods for their use
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
WO2023177974A3 (en) Anti-mesothelin antibodies and uses thereof
WO2001098314A3 (en) Novel motor proteins and methods for their use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition